Long-Term Outcomes of the RELATIVITY-047 Trial

This discussion focuses on the extended follow-up results of a key phase 3 study comparing combination immunotherapy with single-agent treatment in previously untreated advanced melanoma. Panelists review data demonstrating durable responses and survival benefits associated with dual checkpoint blockade, noting that these outcomes are consistent across diverse patient subgroups.

They analyze trends showing sustained benefit over time, including improved progression-free and overall survival compared with single-agent therapy. Importantly, they highlight that the combination’s safety profile remains manageable, with most adverse events being predictable and reversible through established monitoring and intervention strategies.

The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, supporting its use as a foundational approach for eligible patients. Continued follow-up and real-world validation are expected to refine patient selection and optimize management strategies.